Efficacy and safety of bismuth-based quadruple therapy for Helicobacter pylori eradication in children

Helicobacter Pylori

Efficacy and safety of twice a day, bismuth-containing quadruple therapy using high-dose tetracycline and metronidazole for second-line Helicobacter pylori eradication

Helicobacter.

Kim JY, Lee SY, Kim JH, Sung IK, Park HS

doi: 10.1111/hel.12683.

Helicobacter Pylori

Efficacy of bismuth added to standard triple therapy as the first-line eradication regimen for Helicobacter pylori infection

Helicobacter

Kim YJ, Chung WC, Kim DB

doi: 10.1111/hel.12792

Helicobacter Pylori

Non-bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: A real-life study

Helicobacter.

Romano M, Gravina AG, Nardone G, Federico A, Dallio M, Martorano M, Mucherino C, Romiti A, Avallone L, Granata L, Priadko K, Compare D, Tuccillo C, Romito MR, Sgambato D, Miranda A, Romano L, Loguercio C, Bazzoli F, Zagari RM

doi: 10.1111/hel.12694.

Helicobacter Pylori

Comparison of four different regimens against Helicobacter pylori as a first-line treatment: A prospective, cross-sectional, comparative, open trial in Chinese children

Helicobacter.

Zhou Y, Ye Z, Wang Y, Zhang Y, Tang Z, Yan W, Jiang Y, Huang Y

doi: 10.1111/hel.12679.

Helicobacter Pylori

The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: A systematic review and meta-analysis

Helicobacter.

Zou Y, Qian X, Liu X, Song Y, Song C, Wu S, An Y, Yuan R, Wang Y, Xie Y

doi: 10.1111/hel.12714.

Helicobacter Pylori

Twice-a-day PPI, tetracycline, metronidazole quadruple therapy with Pylera® or Lactobacillus reuteri for treatment naïve or for retreatment of Helicobacter pylori. Two randomized pilot studies

Helicobacter.

Dore MP, Bibbò S, Loria M, Salis R, Manca A, Pes GM, Graham DY

doi: 10.1111/hel.12659.

Helicobacter Pylori

Once-daily rabeprazole, levofloxacin, clarithromycin-MR, and bismuth for Helicobacter pylori eradication: A randomized study of 7 or 14 days (ONCE study)

Helicobacter.

Auttajaroon J, Vilaichone RK, Chotivitayatarakorn P, Mahachai V

doi: 10.1111/hel.12615.

Helicobacter Pylori

N-acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication

Cochrane Database Syst Rev.

Fontes LES, Martimbianco ALC, Zanin C, Riera R

doi: 10.1002/14651858.

Helicobacter Pylori

PPI-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta-analysis

Helicobacter.

Gao CP, Zhang D, Zhang T, Wang JX, Han SX, Graham DY, Lu H

doi: 10.1111/hel.12692.

Related content

Efficacy and safety of twice a day, bismuth-containing quadruple therapy using high-dose tetracycline and metronidazole for second-line Helicobacter pylori eradication

Efficacy of bismuth added to standard triple therapy as the first-line eradication regimen for Helicobacter pylori infection

Non-bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: A real-life study

Comparison of four different regimens against Helicobacter pylori as a first-line treatment: A prospective, cross-sectional, comparative, open trial in Chinese children

The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: A systematic review and meta-analysis

Twice-a-day PPI, tetracycline, metronidazole quadruple therapy with Pylera® or Lactobacillus reuteri for treatment naïve or for retreatment of Helicobacter pylori. Two randomized pilot studies

Once-daily rabeprazole, levofloxacin, clarithromycin-MR, and bismuth for Helicobacter pylori eradication: A randomized study of 7 or 14 days (ONCE study)

N-acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication

PPI-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta-analysis